Navigation Links
Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Date:9/5/2007

cations, warnings and precautions, see the Instructions for Use available at http://www.cypherstent.com.

About Cordis Corporation

Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at http://www.cordis.com.

*Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). Rapamune is a trademark of Wyeth Pharmaceuticals.


'/>"/>
SOURCE Cordis Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Data Analyses Outline Efficacy and Safety of Mircera for the Treatment of Renal Anemia Associated With Chronic Kidney Disease
5. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
6. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
7. Genetic Analysis Systems Enter the Clinical Mainstream
8. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
9. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... and BOSTON , December ... leading GPCR structure-guided drug discovery and development company, is ... in the United States relating ... these patents in the US significantly strengthens the global ... major pharmaceutical markets. The suite of patents ...
(Date:12/13/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/2r6bmg/drug_injection ) ... Injection Devices to 2020" report to their ... As new drugs become available for ... conditions, drug developers have increasingly pursued packaging and ... increase the efficiency and reliability with which the ...
(Date:12/13/2014)... , Dec. 12, 2014  Radiologists can transmit ... images, to their referring physicians, electronic health records ... carefully selected technology.  That was ... Systems Corporation (ADS) at the recent Radiology Society ... transmitting of radiology reports in this manner also ...
Breaking Medicine Technology:Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4Advanced Data Systems Presents on Interface-Free EHR Communications at RSNA's 2014 Conference: Streamlining Communication of Reports and Images to Referring Physicians 2Advanced Data Systems Presents on Interface-Free EHR Communications at RSNA's 2014 Conference: Streamlining Communication of Reports and Images to Referring Physicians 3
... to Show That Extended,Thromboprophylaxis Reduces VTE Risk ... 44% , PARIS, July 8, 2007 /PRNewswire-FirstCall/ ... (EXtended CLinical,prophylaxis in Acutely Ill Medical patients) ... in acutely ill medical patients,with reduced mobility ...
... Positive Phase IIa Clinical,Trial Results, First clinical ... in AM-Pharma's Pipeline , BUNNIK, The Netherlands, ... novel therapeutics to treat,infectious and inflammatory diseases, ... Phase IIa Alkaline Phosphatase (AP) trial,for patients ...
Cached Medicine Technology:New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 2New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 4New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 5New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 6AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5
(Date:12/17/2014)... 17, 2014 Project Veritas is releasing ... videos of MIT economist and Obamacare architect Jonathan Gruber ... O’Keefe conducted the interview, which is being distributed on ... was intentional mislabeling in the Affordable Care Act in ... A two-hundred-and-fifty billion dollar per year tax grab. , ...
(Date:12/17/2014)... Alan Mozes HealthDay ... In the world of infectious diseases, one worrisome phenomenon is ... people. The process -- known as zoonosis -- is ... look for signs that an animal-borne disease might make inroads ... just such a development -- and the culprits in this ...
(Date:12/17/2014)... 2014 (HealthDay News) -- Poor students get more fruits and ... study finds. But, the opposite is true for students ... and vegetables at school may give a healthy boost to ... matter what the family income level, students all ate a ... found. The study was published recently in the journal ...
(Date:12/17/2014)... By Alan Mozes ... -- With the holiday party season fast approaching, a new ... and make DUI arrests have fewer drunk drivers on their ... driving laws more vigilantly are better able to deter inebriated ... "Hardly any new laws are being passed regarding drinking ...
(Date:12/17/2014)... Kathleen Doheny HealthDay Reporter ... loss is rampant in America, and work commitment is a ... No. 1 sleep killer," said Dr. Mathias Basner, an assistant ... of Pennsylvania Perelman School of Medicine. A time-use survey ... that work is the main activity exchanged for sleep. Short ...
Breaking Medicine News(10 mins):Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3
... science at high school has just become a little more ... from the University of Bath have found that a protein ... a cell divides in two. , In research published in ... shown that the protein is essential for building the microtubules ...
... of The Walter and Eliza Hall Institute, Professor Suzanne ... of the 2008 Thomson Scientific Citation Awards announced at ... Scientific, a US-based international information analysis company, states that ... that identifies the average number of citations per paper ...
... Heart Associations Los Angeles Division today will honor John ... in use around the country and one of the ... Harbor-UCLA Medical Center (LA BioMed). , The association will ... Criley and William Koenig, Los Angeles County Emergency Medical ...
... site heralds AAGL commitment to patient education, ... professional,organization of gynecologists interested in endoscopy and minimally,invasive ... and added a,comprehensive patient education section on ... to treat them. The site,continues to provide physician ...
... ... WHITE PLAINS, N.Y., April 3, 2008 Head lice is ... common,cold.(1) There are about 6 to 12 million cases each year,(2) ... days annually.(3),But, now parents can say good-bye to head lice and ...
... April 3, 2008 Mach One,Corporation, http://www.machonecorp.com, ... prior to large scale manufacturing of its ImmunoGam(TM),colostrum ... highly qualified scientist from BioQual spent a week ... technology transfer and,memorializing the protocols for manufacture of ...
Cached Medicine News:Health News:Mitosis gets harder thanks to new gene discovery 2Health News:Professor Suzanne Cory honored with national citation award 2Health News:Pioneer of paramedic model to be honored 2Health News:Pioneer of paramedic model to be honored 3Health News:Women Can Now Learn About Minimally Invasive Gynecologic Treatments at AAGL.org 2Health News:Women Can Now Learn About Minimally Invasive Gynecologic Treatments at AAGL.org 3Health News:Women Can Now Learn About Minimally Invasive Gynecologic Treatments at AAGL.org 4Health News:New Breakthrough Treatment is Tough On Lice But Gentle On Kids 2Health News:New Breakthrough Treatment is Tough On Lice But Gentle On Kids 3Health News:Mach One Corporation Announces Completion of Final Tests Prior to Full Scale Production 2
Compression Bra...
Post-Surgical compression garments...
... The Albumin Cobalt Binding (ACB®) Test is ... Modified Albumin (IMA®) by measuring the cobalt ... serum sample. First identified in the early ... comes in contact with ischemic tissue in ...
... Test is a clinical chemistry assay that ... the cobalt binding capacity of albumin in ... the early 1990s, IMA is produced when ... tissue in the heart. During ischemia, the ...
Medicine Products: